Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Transplantation
Volume 2012, Article ID 513025, 4 pages
http://dx.doi.org/10.1155/2012/513025
Case Report

Absence of mTOR Inhibitor Effect on Hepatic Cyst Growth: A Case Report of a Kidney Transplant Recipient with Autosomal Dominant Polycystic Kidney Disease

Centre de Transplantation d'Organes, Centre Hospitalier Universitaire Vaudois, Avenue du Bugnon 46, 1011 Lausanne, Switzerland

Received 6 November 2012; Accepted 28 November 2012

Academic Editors: C. F. Classen, C. Costa, and C. Sommerer

Copyright © 2012 L. Friedrich et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. E. Torres, P. C. Harris, and Y. Pirson, “Autosomal dominant polycystic kidney disease,” The Lancet, vol. 369, no. 9569, pp. 1287–1301, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. A. B. Chapman, “Autosomal dominant polycystic kidney disease: time for a change?” Journal of the American Society of Nephrology, vol. 18, no. 5, pp. 1399–1407, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Lespinasse, J. Fourcade, and F. Schir, “La génétique des polykystoses rénales: mise au point et conseil génétique,” Néphrologie & Thérapeutique, vol. 2, no. 3, pp. 120–126, 2006. View at Google Scholar
  4. J. J. Grantham, V. E. Torres, A. B. Chapman et al., “Volume progression in polycystic kidney disease,” The New England Journal of Medicine, vol. 354, no. 20, pp. 2122–2130, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. Q. Qian, H. Du, B. F. King et al., “Sirolimus reduces polycystic liver volume in ADPKD patients,” Journal of the American Society of Nephrology, vol. 19, no. 3, pp. 631–638, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Canaud, B. Knebelmann, P. C. Harris et al., “Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: what is the appropriate serum level?” American Journal of Transplantation, vol. 10, no. 7, pp. 1701–1706, 2010. View at Google Scholar · View at Scopus
  7. N. Perico, L. Antiga, A. Caroli et al., “Sirolimus therapy to halt the progression of ADPKD,” Journal of the American Society of Nephrology, vol. 21, no. 6, pp. 1031–1040, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. A. L. Serra, D. Poster, R. P. Wuthrich et al., “Sirolimus and kidney growth in autosomal dominant polycystic kidney disease,” The New England Journal of Medicine, 2010. View at Google Scholar
  9. G. Walz, K. Budde, M. Mannaa et al., “Everolimus in patients with autosomal dominant polycystic kidney disease,” The New England Journal of Medicine, vol. 363, no. 9, pp. 830–840, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. Q. He, C. Lin, J. Chen et al., “Efficacy and safety of mTOR inhibitor therapy in patients with early-stage autosomal dominant polycystic kidney disease: a meta-analysis of randomized controlled trials,” The American Journal of the Medical Sciences, vol. 344, no. 6, pp. 491–497, 2012. View at Publisher · View at Google Scholar
  11. Z. Novali, A. M. Van der Wal, D. J. M. Peters et al., “Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease,” Journal of the American Society of Nephrology, vol. 23, no. 5, pp. 842–853, 2012. View at Google Scholar